Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: A phase II study in patients with nonresectable liver metastases from colorectal cancer

Annals of Oncology

Volumn 14, Issue 6, 2003, Pages 856-863

  Fallik, D ^a   Ychou, M ^b   Jacob, J ^c   Colin, P ^d   Seitz, J F ^e   Baulieux, J ^f   Adenis, A ^g   Douillard, J Y ^h   Couzigou, P ⁱ   Mahjoubi, R ^a   Ducreux, M ^a   Mahjoubi, M ^j   Rougier, Philippe ^a,k  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE VAL D AURELLE   (France)

^c CENTRE FRANÇOIS BACLESSE   (France)

^d Clinique Courlancy   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f CROIX ROUSSE HOSPITAL   (France)

^g CENTRE OSCAR LAMBRET   (France)

^h CENTRE RENÉ GAUDUCHEAU   (France)

ⁱ BORDEAUX UNIVERSITY HOSPITAL   (France)

^j SANOFI   (France)

^k HÔPITAL AMBROISE PARÉ   (France)

more..

Author keywords

Colorectal cancer; Hepatic arterial chemotherapy; Liver metastases; Pirarubicin

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; FLUOROURACIL; FOLINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PIRARUBICIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTERY CATHETERIZATION; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATIC ARTERY; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DOXORUBICIN; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 0038012186     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg247     Document Type: Article

References (35)

1. Wagner JS, Adson MA, Van Heerden JA et al. The natural history of hepatic metastases from colorectal carcinoma. A comparison with resective treatment. Ann Surg 1984; 199: 502-508.
2. Colonna M, Grosclaude P, Faivre J et al. Cancer registry data based estimation of regional cancer incidence: application to breast and colorectal cancer in French administrative regions. J Epidemiol Community Health 1999; 53: 558-564.
3. Rougier P, Milan C, Lazorthes F et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg 1995; 82: 1397-1400.
4. Kemeny N. Review of regional therapy of liver metastases in colorectal cancer. Semin Oncol 1992; 19: 155-162.
5. Rougier P, Lasser P, Elias D. Bases rationnelles et résultats de la chimiothérapie intra-artériele. Ann Chir 1988; 42: 639-646.
6. Taylor I, Bennett R, Sherriff S. The blood supply of colorectal liver metastases. Br J Cancer 1978; 38: 749-756.
7. Kemeny MM, Goldberg D, Beatty JD et al. Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer 1986; 57: 492-498.
8. Chang AE, Schneider PD, Sugarbaker PH et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206: 685-693.
9. Kemeny N, Daly J, Reichman B et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987; 107: 459-465.
10. Hohn DC, Stagg RJ, Friedman MA et al. A randomized trial of continuous intravenous versus hepatic intra-arterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Onconlogy Group trial. J Clin Oncol 1989; 7: 1646-1654.
11. Martin JK Jr, O'Connell MJ, Wieand HS et al. Intra-arterial floxuridine versufs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125: 1022-1027.
12. Rougier P, Laplanche A, Huguier M et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992; 10: 1112-1118.
13. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of non resectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88: 252-258.
14. Allen-Mersh TG, Earlam S, Forfy C et al. Quality of life and survival with continuous hepatic-artery floxiuridine infusion for colorectal liver metastases. Lancet 1994; 344: 1255-1260.
15. Earlam S, Glover C, Davies M et al. Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients. J Clin Oncol 1997; 15: 2022-2029.
16. Durand-Zaleski I, Roche B, Buyse M et al. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. J Natl Cancer Inst 1997; 89: 790-795.
17. Munck JN, Riggi M, Rougier P et al. Pharmacokinetic and pharmacodynamic advantages of Pirarubicin over adriamycin after intra-arterial hepatic administration in the rabbit VX2 tumor model. Cancer Res 1993; 53: 1550-1554.
18. Munck JN, Rougier P, Chabot GG et al. Phase I and pharmacological study of intra-arterial hepatic administration of Pirarubicin in patients with advanced hepatic metastases. Eur J Cancer 1994; 30A: 289-294.
19. Rougier P, Munck JN, Elias D et al. Intra-arterial hepatic chemotherapy with Pirarubicin. Preclinical and clinical studies. Am J Clin Oncol 1990; 13: S1-S4.
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
21. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
22. Kemeny N, Huang Y, Cohen AM et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039-2048.
23. Elias D, Ducreux M, Rougier P et al. Chimiothérapie intra-artérielle hépatique. Expérience de 200 cas. Gastroenterol Clin Biol 1994; 18: 975-982.
24. Lorenz M, Müller HH for the German Cooperative Group on Liver Metastases. Randomized, multicenter trial of fluorouracil plus leucovorin administrated either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administrated via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000; 18: 243-254.
25. Safi F, Bittner R, Roscher R et al. Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intra-arterial versus continuous intra-arterial/intravanous therapy). Result of a controlled clinical trial. Cancer 1989; 64: 379-387.
26. O'Connell MJ, Nagorney DM, Bernath AM et al. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 1998: 16: 2528-2533.
27. Howell JD, McArdle CS, Kerr DJ et al. A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases. Br J Cancer 1997; 76: 1390-1393.
28. Howell JD, Warren HW, Anderson JH et al. Intra-arterial 5-fluorouracil and intravenous folinic acid in the treatment of liver metastases from colorectal cancer. Eur J Surg 1999; 165: 652-658.
29. Warren HW, Anderson JH, O'Gorman P et al. A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases. Br J Cancer 1994; 70: 677-680.
30. Makela J, Kantola R, Tikkakoski T et al. Superselective intra-arterial chemotherapy with mitomycin C in hepatic metastases from colorectal cancer. J Surg Oncol 1997; 65: 127-131.
31. Cantore M, Aitini E, Rabbi C et al. Combined intra-arterial locoregional and systemic treatment of nonresectable hepatic metastases of colorectal carcinoma. G Chir 1997; 18: 235-239.
32. Kemeny N, Cohen A, Seiter K et al. Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J Clin Oncol 1993; 11: 330-335.
33. Link KH, Pillasch J, Formentini A et al. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases. Eur J Surg Oncol 1999; 25: 381-388.
34. Focan C, Levi F, Kreutz F et al. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. Anticancer Drugs 1999; 10: 385-392.
35. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol 1997; 15: 808-815.